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Chronic inflammation triggered 
by the NLRP3 inflammasome in 
myeloid cells promotes growth 
plate dysplasia by mesenchymal 
cells
Chun Wang1, Can-Xin Xu2, Yael Alippe1, Chao Qu1, Jianqiu Xiao1, Ernestina Schipani3, Roberto 
Civitelli1, Yousef Abu-Amer4 & Gabriel Mbalaviele1
Skeletal complications are common features of neonatal-onset multisystem inflammatory disease 
(NOMID), a disorder caused by NLRP3-activating mutations. NOMID mice in which NLRP3 is activated 
globally exhibit several characteristics of the human disease, including systemic inflammation and 
cartilage dysplasia, but the mechanisms of skeletal manifestations remain unknown. In this study, we 
find that activation of NLRP3 in myeloid cells, but not mesenchymal cells triggers chronic inflammation, 
which ultimately, causes growth plate and epiphyseal dysplasia in mice. These responses are IL-1 
signaling-dependent, but independent of PARP1, which also functions downstream of NLRP3 and 
regulates skeletal homeostasis. Mechanistically, inflammation causes severe anemia and hypoxia in the 
bone environment, yet down-regulates the HIF-1α pathway in chondrocytes, thereby promoting the 
demise of these cells. Thus, activation of NLRP3 in hematopoietic cells initiates IL-1β-driven paracrine 
cascades, which promote abnormal growth plate development in NOMID mice.
NLRP3-activating mutations cause cryopyrin-associated periodic syndromes (CAPS) of which neonatal-onset 
multisystem inflammatory disease (NOMID) is the most severe manifestation1, 2. Each of these rare, but serious 
cryopyrinopathy phenotypes is associated with excessive interleukin (IL)-1β and IL-18 production, unprovoked 
recurrent episodes of fever, urticaria-like rash, arthropathy and CNS symptoms1, 2. In addition, skeletal anomalies 
are prominent features of NOMID, which include osteopenia, bone deformities, leg length discrepancy and short 
stature3–6. These defects are associated with abnormal epiphyseal calcification and outgrowths, and growth plate 
disorganization, but the underlying mechanisms are not understood.
Activated NLRP3 assembles a protein complex, the NLRP3 inflammasome, which processes pro-IL-1β and 
pro-IL-18 into biologically active, IL-1β and IL-18, respectively7, 8. As other members of the inflammasome family, 
NLRP3 is synthesized by innate immune cells, and its expression is robustly up-regulated upon NF-κB activation9, 10. 
Activating-mutations of NLRP3 causing cryopyrinopathies have been linked to abnormal NLRP3 function in 
myeloid cells11, 12. The NLRP3 inflammasome is also active in mesenchymal cells, including osteoblasts and chon-
drocytes6, 13, 14. These cells maintain skeletal integrity through the production, organization and mineralization of 
the extracellular matrix; but aberrant activities of these cells in pathologic conditions such as osteoarthritis can 
cause degenerative hypertrophy such as osteophytes and Heberdeen’s nodes. Indeed, enhanced cAMP-dependent 
protein kinase activity and Wnt signaling in stromal cells/osteoblasts may contribute to the tumor-like phenotype 
of bony outgrowths in NOMID patients15, 16; and hyper-activation of the NLRP3 inflammasome is presumed to 
promote chondrocyte apoptosis, thereby contributing to deafness in CAPS patients6, 17. Thus, it is possible that 
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growth plate and epiphyseal dysplasia in NOMID may arise from aberrant NLRP3 actions in mesenchymal cells 
in addition to indirect effects via innate immune cells.
Consistent with the NLRP3 inflammasome’s role in over-secretion of IL-1β and IL-18 in CAPS patients18, 
IL-1 biologics are used for the treatment of these disorders19. Intriguingly, recent reports indicate that skeletal 
lesions in NOMID patients progress despite treatment with IL-1β blocking agents, while other symptoms related 
to systemic inflammation rapidly resolve20–23. These observations suggest that multiple effectors of this inflam-
masome influence the development of skeletal abnormalities. This view is consistent with the emerging evidence 
that the NLRP3 inflammasome signaling cascades promote the processing of numerous substrates, including 
poly(ADP-ribose) polymerase 1 (PARP1), a protein that negatively regulates bone resorption through inhibition 
of osteoclast differentiation24–27. Thus, the mechanisms leading to the skeletal abnormalities in cryopyrinopathies 
are still unclear.
NOMID mice in which NLRP3 is activated globally phenocopy the skeletal defects of the human disorder, but 
the underlying mechanisms remain unknown. In this study, we conditionally activated the NLRP3 inflammasome 
either in the mesenchymal or hematopoietic lineage. We found that activation of this inflammasome in myeloid 
cells, but not mesenchymal cells in mice causes inflammation, and growth plate and epiphyseal dysplasia through 
IL-1β- dependent mechanisms.
Results
Constitutive activation of the NLRP3 inflammasome in mesenchymal cells does not cause 
inflammation or abnormal growth plate development. We have previously reported a murine model 
of NOMID in which NLRP3 was constitutively activated globally as a result of the mating of Nlrp3fl(D301N)/+ mice 
with mice expressing Cre under the control of the Zona pelucida 3 (ZP) promoter (NLRP3ZP)14. D301N is the 
ortholog of the D303N mutation that occurs in NOMID patients. Nlrp3ZP mice exhibited several features of 
NOMID patients, including systemic inflammation and disorganized growth plate and epiphysis14 (Figure S1A). 
In agreement with these findings, arthropathy and osteolysis have also been reported recently in mice in which 
the endogenous Nlrp3 locus was replaced by the human mutated NLRP3 locus, also referred to as humanized 
mice28. To determine the contribution of chondrocyte to this phenotype, we generated mice in which the inflam-
masome was activated constitutively in chondrocytes by Collagen II-Cre (NLRP3Col2). Nlrp3Col2 mice developed 
normally and were indistinguishable from neonatal and adult wild-type (WT) littermates based on histological 
assessment of the growth plate and epiphysis (Figure S1B–E) and micro-computed tomography (µCT) analy-
sis of the subchondral bone (Figure S2A). Given that stromal cells/osteoblasts and chondrocytes are the only 
cells capable of forming the bony outgrowths found in NOMID patients6, 13, we therefore activated NLRP3 in 
common chondrocyte and osteoblast progenitors using Twist-2/Dermo-1-Cre (DM1) to generate Nlrp3DM1 mice. 
Unexpectedly, growth plate development (data not shown), and bone mass accrual (Figure S2B) were comparable 
between WT and Nlrp3DM1 mice.
NLRP3 expression in myeloid cells is controlled by NF-κB9, 10, which is activated predominantly by IKK2 in 
inflammatory conditions29. We therefore hypothesized that lack of skeletal abnormalities in Nlrp3 mice might be 
related to the so-called priming signals, which are necessary to activate NF-κB; perhaps the priming signals are 
too low in osteochondro-progenitors in homeostatic states. We tested this premise by generating Nlrp3fl(D301N)/+; 
Ikk2fl/fl; DM1-Cre (Nlrp3DM1; Ikk2DM1) mice, in which the NF-κB pathway is also constitutively activated30. Despite 
efficient recombination of the mutant Nlrp3 allele in epiphyseal cartilage (Figure S2C), expression of NLRP3 and 
IL-1β (Figure S2D), and IL-18 (data not shown) in samples from 4-week-old WT mice was not different than 
in Nlrp3DM1, Ikk2DM1 or Nlrp3DM1; Ikk2DM1 mice. Given that Gr1 and CD11b are highly expressed by neutro-
phils, and neutrophilia occurred in cryopyrinopathies14, 25, 28, 31, we focused on the expression of these markers to 
assess inflammation. The percentage of Gr1+/CD11b+ cells was increased slightly, but significantly in Nlrp3DM1, 
Ikk2DM1 or Nlrp3DM1; Ikk2DM1 mice relative to WT mice (Fig. 1A and B). This increase was also significant between 
Nlrp3DM1; Ikk2DM1 and Nlrp3DM1 mice, but not Nlrp3DM1; Ikk2DM1 and Ikk2DM1 mice, suggesting the dominance of 
IKK2 actions, some of which were unrelated to the NLRP3 inflammasome. The inability of NLRP3DM1 to induce 
adequate inflammation in vivo was consistent with the equivalent levels of IL-1β induced in vitro by TNF-α in 
bone marrow stromal cells, the precursors of chondrocytes and osteoblasts, isolated from WT, individual or com-
pound mutant mice (data not shown). IL-1β production by bone marrow macrophages (BMM) in vitro was also 
not different among genotypes (Fig. 1C), as expected.
Histological assessment of the growth plate revealed no apparent patterning defects between WT and mutant 
mice (Fig. 1D). Likewise, subchondral bone development was also unaffected, though bone mass was lower in 
Ikk2DM1 and Nlrp3DM1; Ikk2DM1 mice compared to WT or Nlrp3DM1 mice (Fig. 1E and Figure S2E). Collectively, 
these results indicate that some bone effects of IKK2 are NLRP3 inflammasome-independent. In addition, 
activation of this inflammasome in mesenchymal cells does not cause inflammation or skeletal abnormalities, 
implying that cartilage dysplasia in NOMID mice is not triggered by chondrocyte autonomous actions of the 
inflammasome.
Constitutive activation of the NLRP3 inflammasome in myeloid cells causes inflammation 
and growth plate defects independently of PARP1. Poly(ADP-ribose) polymerase 1 (PARP1) is 
cleaved upon NLRP3 inflammasome activation, a response that is blunted by the D214N substitution in PARP1 
(PARP1D214N) as we recently reported24. We also found that PARP1 regulates skeletal development24, 32, but 
whether PARP1 interacts with NLRP3 during this process remains unknown. Here, we used Parp1D214N/D214N mice 
to investigate the interplay between this protein and NLRP3. Consistent with our previous report25, activation of 
NLRP3 in myeloid cells driven by Cre under the control of the lysozyme M promoter (NLRP3LysM) resulted in a 
significant increase in the percentage of Gr1+/CD11b+ cells in Nlrp3LysM mice (Fig. 2A and B), which usually died 
2–3 weeks after birth. PARP1D214N expression had no impact on the survival of Nlrp3 mice (data not shown) and 
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never altered the profile of Gr1+/CD11b+ cells at baseline nor in response to inflammasome activation (Fig. 2A 
and B), suggesting that PARP1 is not involved in NLRP3-mediated inflammatory responses. Accordingly, IL-1β 
production induced in vitro by the inflammasome activator, ATP, was comparable between WT and Parp1D214N/
D214N BMM (Fig. 2C). Moreover, PARP1D214N failed to affect the secretion of this cytokine driven by NLRP3LysM, 
which did not require the presence of the nucleotide (Fig. 2C).
Strikingly, histological examinations of the femurs showed disorganized columns of chondrocytes with pro-
foundly altered morphology in the growth plate of 2-week-old Nlrp3LysM mice (Fig. 2D, bracket and Figure S3A 
and B). The extracellular matrix protruded from the center of the growth plate towards the bone marrow cavity 
(Figure S3A and B, asterisk). These cartilage remnants were calcified to some extent since they were also detected 
Figure 1. Constitutive activation of the NLRP3 inflammasome in osteochondro-progenitors does not cause 
inflammation and abnormal growth plate development. All data were obtained from 4-week old WT, Nlrp3DM1, 
Ikk2DM1 or Nlrp3DM1; Ikk2DM1 male mice (n = 3–10/genotype). (A) Red blood cell-depleted bone marrow cells 
were stained with isotype control (data not shown) or with antibodies against CD11b and Gr1. Representative 
flow cytometry dot plots of the CD11b+/Gr1+ myeloid cells from each genotype are shown. (B) The percentage 
of CD11b+/Gr1+ cells in bone marrow cells. Data are expressed as mean ± SEM. *P < 0.05; **P < 0.005. (C) 
IL-1β levels in conditioned media from BMM treated with 100 ng/ml LPS for 3 hours, then with 5 mM ATP for 
30 minutes. Data are expressed as mean ± SD of 3 independent experiments carried out in triplicates. NS, not 
significant. (D) H&E staining. GP, growth plate. Scale bar, 100 µm. (E) 3D μCT reconstruction of distal femoral 
metaphysis. Scale bar, 1 mm.
www.nature.com/scientificreports/
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Figure 2. Constitutive activation of the NLRP3 inflammasome in myeloid cells causes inflammation and 
growth plate defects independently of PARP1. All data were obtained from 2-week old WT, Nlrp3LysM, 
Parp1D214N/D214N or Nlrp3LysM; Parp1D214N/D214N male mice (n = 3–4/genotype). (A) Red blood cell-depleted bone 
marrow cells were stained with isotype control (data not shown) or with antibodies against CD11b and Gr1. 
Representative flow cytometry dot plots of the CD11b+/Gr1+ myeloid cells from each genotype are shown.  
(B) The percentage of CD11b+/Gr1+ cells in bone marrow cells. Data are expressed as mean ± SEM. 
**P < 0.005. NS, not significant. (C) IL-1β levels in conditioned media from BMM treated with 100 ng/ml 
LPS for 3 hours, then with 5 mM ATP for 30 minutes. Data are representative of at least three independent 
experiments and expressed as mean ± SEM. $P < 0.001 vs. WT + LPS. (D) H&E staining. Red circle and bracket 
indicate areas of hypocellularity within the enlarged center of the epiphysis and growth plate disorganization, 
respectively. Scale bar, 150 µm. (E) 3D μCT reconstruction of distal femoral metaphysis. Scale bar, 0.5 mm.
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by µCT imaging (Fig. 2E, arrow and S3C, arrow). In addition, the center of the epiphysis in mutant mice was 
enlarged and markedly hypocellular (Fig. 2D and Figure S3B, red circle) as in Nlrp3ZP mice, a phenotype caused 
by massive chondrocyte death14. In agreement with the observations above, the phenotype of Nlrp3LysM mice was 
unaffected by PARP1D214N expression (Fig. 2D and E; Figure S3A–C). Thus, activation of NLRP3 causes severe 
inflammation and aberrant chondrocyte development independently of PARP1. Furthermore, the similarity of 
the phenotype of Nlrp3LysM and Nlrp3ZP mice14, but not Nlrp3DM1 or Nlrp3col2, suggests that cartilage abnormalities 
in NOMID mice are indirect consequences of NLRP3 inflammasome activation in myeloid cells.
Constitutive activation of the NLRP3 inflammasome in myeloid cells causes inflammation and 
growth plate defects through IL-1 signaling. The efficacy of IL-1 biologics in clinic for the treatment of 
auto-inflammatory disorders, including CAPS, provides a strong rationale for focusing on IL-1 pathway and lev-
eraging the availability of Il-1 receptor (Il-1r) null mice to determine the role of this cytokine in NLRP3-induced 
skeletal manifestations. Il-1r−/− mice are unresponsive to IL-1β and develop normally. We found that the percent-
age of Gr1+/CD11b+ cells was comparable between WT and Il-1r−/− mice at baseline, but Nlrp3LysM-induced neu-
trophilia was blunted by Il-1r ablation (Fig. 3A). Furthermore, whereas loss of Il-1r also had no effect on skeletal 
metabolism at baseline, it prevented growth plate and epiphyseal dysplasia induced by NLRP3LysM (Fig. 3B and 
C). Thus, IL-1 signaling plays a major role in cartilage complications associated with NLRP3 hyper-activation.
Constitutive activation of the NLRP3 inflammasome in myeloid cells causes anemia of inflam-
mation through IL-1 signaling. Nlrp3LysM mice exhibited systemic inflammation characterized by an 
increased number of white blood cells (Fig. 4A) associated with neutrophilia (Fig. 4B), thrombocytosis (Fig. 4C), 
lymphopenia (Fig. 4D), and anemia (Fig. 4E). Accordingly, the bone marrow compartment of Nlrp3LysM mice con-
tained abnormally low levels of Ter119+ cells (Fig. 4F and G) and CD71+ erythroid progenitors (data not shown). 
Alterations of hematopoietic cell lineages also occurred in the spleens of Nlrp3LysM mice as Gr1+/CD11b+ subsets 
were increased (Figure S4A and B) while Ter119+ cells were decreased (Figure S4C and D), responses associated 
with an increase in spleen size in mutant mice (Fig. 4H–M; Figure S4E and F; bottom panels). Consistent with 
the view that IL-1 drives the disease in Nlrp3LysM mice, anemia (Figure S4E and F; top panels) and splenomegaly 
(Fig. 4H–M; Figure S4E and F, bottom panels) were prevented by Il-1r deletion, but not PARP1D214N expression. 
Thus, NLRP3LysM expression promotes an inflammatory and anemic environment in bone marrow through the 
IL-1 pathway.
Constitutive activation of the NLRP3 inflammasome in myeloid cells impairs chondrocyte 
responses to hypoxia. The center of the epiphysis of developing limbs is avascular and highly hypoxic33. 
We assessed the binding of hypoxyprobe, which detects areas of hypoxia in tissues34 to test the hypothesis that 
hypoxia may be exacerbated in the anemic environment promoted by NLRP3LysM expression. We found that 
more chondrocytes in the epiphysis of 2-week-old Nlrp3LysM mice were labelled by the hypoxyprobe compared 
to sex- and age-matched WT mice (Fig. 5A, brown staining). Hence, we determined the impact of exaggerated 
hypoxia by analyzing the expression of hypoxia-induced factor-1α (HIF-1α) and its targets in the epiphysis. 
Despite hypoxia, the expression of HIF-1α and its target genes, vascular endothelial growth factor (VEGF), car-
bonic anhydrase 9 (Ca9), phosphoglycerate kinase 1 (PGK1), glucose transporter 1 (Glut1) and BCL2/adenovirus 
E1B 19 kDa protein-interacting protein 3 (Bnip3) was reduced in Nlrp3LysM mice relative to WT mice (Fig. 5B). 
Consistent with these results, the number of chondrocytes devoid of HIF-1α protein was higher in the epiphyses 
of Nlrp3ZP mice compared to WT mice (Figure S5). Thus, NLRP3 activation in myeloid cells generates paracrine 
signals, which inhibit the expression of HIF-1α and its targets in chondrocytes, thereby impairing responses to 
hypoxia.
To further strengthen our proposition that IL-1β is the main culprit of NLRP3LysM skeletal actions, we ana-
lyzed its expression in bone marrow. IL-1β levels were consistently higher in bone marrow supernatants from 
Nlrp3LysM mice relative to WT mice, but were comparable to those of Nlrp3LysM; Il-1r−/− mice (Fig. 6A), suggesting 
that IL-1β signaling, but not production was impaired in compound mutant mice. To model the in vivo environ-
ment in which chondrocytes were exposed to excessive IL-1β levels, we studied the effects of IL-1β treatment 
on chondrocytes in vitro. PARP1 cleavage, an indicator of apoptosis, was induced by IL-1β, a response that was 
enhanced slightly when the cultures were carried out under hypoxic conditions (Fig. 6B). IL-1β also stimulated 
the expression of HIF-1α and its regulated genes in these cells in normoxia, but the amplitude of IL-1β-induced 
responses was attenuated in hypoxic conditions for most of these targets (Figure C–H). Thus, in an inflammatory 
and hypoxic milieu, the ability of chondrocytes to up-regulate genes of the HIF-1α pathway is compromised.
Hypoxia up-regulated IL-1β production by promoting the expression of NLRP3 and absent in melanoma 2 
(AIM2)35, 36. Consistent with these reports, we found that hypoxia enhanced IL-1β production induced by LPS 
and ATP in WT and Nlrp3LysM BMM (Fig. 6I), a response that correlated with increased expression of WT and 
mutant NLRP3 (Fig. 6J). Likewise, IL-1β over-secretion by Nlrp3LysM BMM in the absence of ATP inversely cor-
related with low oxygen levels (Fig. 6I). Collectively, these data suggest that over-secretion of IL-1β by Nlrp3LysM 
myeloid cells, promotes chondrocyte death and causes hypoxia, which in turns sustains inflammation.
Discussion
We find that conditional activation of the NLRP3 inflammasome in chondrocytes or osteochondro-progenitors 
has no detrimental impact on skeletal development in mice. Thus, the growth plate abnormalities observed in 
mice with global NLRP3 activation are not caused by an action of NLRP3 in the mesenchymal lineage. This obser-
vation is intriguing since NLRP3 is highly expressed in chondrocytes and osteoblasts, both of which arise from 
common mesenchymal progenitors. Indeed, hyper-activation of the NLRP3 inflammasome is associated with 
chondrocyte apoptosis, which has been hypothesized to cause deafness in NOMID patients6, 17. Furthermore, 
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cultured stromal cells/osteoblasts from NOMID patients express higher levels of gene targets of the potent bone 
anabolic molecules, Wnts, and are more proliferative than control cells16. Accordingly, induced pluripotent stem 
cells from NOMID patients exhibit superior chondrogenic potential in vitro compared to normal cells15. Thus, 
hyper-active NLRP3 is apparently harmful to human, but not murine osteochondro-progenitors. Whether these 
dissimilar outcomes reflect differences in the experimental approaches (in vitro studies with human NOMID cells 
vs. in vivo studies in NOMID mice) is unclear.
We made the unexpected observation that activation of NLRP3 in myeloid cells (NLRP3LysM) causes not 
only the common symptoms of CAPS, such as excessive IL-1β production and systemic inflammation, but also 
Figure 3. Constitutive activation of the NLRP3 inflammasome in myeloid cells causes inflammation and 
growth plate defects through IL-1 signaling. All data were obtained from 2-week-old WT, Nlrp3LysM, Il-
1r−/− or Nlrp3LysM; Il-1r−/− male mice (n = 4/genotype). (A) Red blood cell-depleted bone marrow cells were 
stained with isotype control (data not shown) or with antibodies against CD11b and Gr1. Representative flow 
cytometry dot plots of the CD11b+/Gr1+ myeloid cells from each genotype are shown. (B) Safranin O staining. 
Red circle and bracket indicate areas of hypocellularity within the enlarged center of the epiphysis and growth 
plate disorganization, respectively. Scale bar, 100 µm. (C) 3D μCT reconstruction of distal femoral metaphysis. 
Scale bar, 0.5 mm.
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Figure 4. Constitutive activation of the NLRP3 inflammasome in myeloid cells causes anemia of inflammation 
through IL-1 signaling. All data were obtained from 2-week old WT or mutant male mice. (A–E) Cell blood 
counts (n = 4 mice/genotype). WBC, white blood cell counts, RBC, red blood cell counts. (F) Bone marrow cells 
(n = 4 mice/genotype) were stained with isotype control (data not shown) or with antibodies against CD11b and 
Ter119. Representative flow cytometry dot plots of CD11b+ myeloid cells or Ter119+ erythrocytes from each 
genotype are shown. (G) The percentage of Ter119+ erythrocytes in bone marrow cells. Data are expressed as 
mean ± SEM. *P < 0.05; **P < 0.005. (H) Body weight. (I) Spleen weight. (J) Percent of spleen weight (spleen 
weight was normalized to body weight). Quantitative data (H–J) were obtained from 5–6 mice/genotype and 
expressed as the mean ± SEM. *P < 0.05; **P < 0.005. (K) Body weight. (L) Spleen weight. (M) Percent of spleen 
weight. Quantitative data (K–M) were obtained from 3–5 mice/genotype and expressed as the mean ± SEM. 
**P < 0.005. NS, not significant.
www.nature.com/scientificreports/
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Figure 5. Activation of NLRP3 in myeloid cells impairs chondrocyte responses to hypoxia. (A) Femoral 
sections from 2-week-old WT or Nlrp3LysM male mice injected with hydroxyprobe were stained with IgG or 
hydroxyprobe antibody. A specimen from renal medulla was used as a positive control. Staining is indicated 
by the brown color. HZ, hypertrophic zone. (B) qPCR analysis of mRNA isolated from mouse epiphyses. 
Quantitative data were obtained from 2–3 mice/genotype and expressed as the mean ± SEM. *P < 0.05; 
**P < 0.005.
www.nature.com/scientificreports/
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Figure 6. Activation of NLRP3 in myeloid cells causes excessive production of IL-1β, a cytokine that promotes 
chondrocyte death. (A) Bone marrow cells were centrifuged at 400 × g, and the supernatants were harvested 
for IL-1β measurement. **P < 0.005. (B) Western blot analysis of the effects of IL-1β on PARP1 cleavage in 
chondrocytes. Cells were treated with IL-1β for 24 hours. β-actin was used as loading control. Cont, control. 
qPCR analysis of the expression of HIF-1α (C), VEGF (D), Ca9 (E), PGK1 (F), Glut1 (G) and Binp3 (H). 
RNA were isolated from murine chondrocytes from the ribs of 2-day old pups. Data are expressed as the 
mean ± SEM. *P < 0.05; **P < 0.005; Cont, control. Rel, relative. NS, not significant. ELISA analysis of IL-1β 
levels in conditioned media (I) and Western blot analysis of NLRP3 expression (J) from BMM treated with 
100 ng/ml LPS for 3 hours, then with 5 mM ATP for 30 minutes in normoxic or hypoxic conditions. Data 
are representative of 2–3 independent experiments and expressed as mean ± SEM. *P < 0.05; **P < 0.005; 
$P < 0.001 vs. WT normoxia + LPS.
www.nature.com/scientificreports/
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cartilage anomalies. The phenotype of Nlrp3LysM mice resembles that of mice broadly expressing the transgene 
(NLRP3ZP), though it is more penetrant in Nlrp3ZP mice. More importantly, cartilage dysplasia in Nlrp3LysM and 
Nlrp3ZP mice recapitulates several features of the human disease, including growth plate disorganization, epiphy-
seal hypocellularity and perinatal onset of the lesions, which are prominent in the distal femoral epiphysis5. In 
addition, murine growth plate protrusions are abnormally calcified similar to the human counterparts as they 
contain components of cartilage and bone extracellular matrices, based on alcian blue staining and µCT analysis, 
respectively. Given that the enlargement of the epiphyses in NOMID children worsens overtime, it is tempting to 
speculate that these protrusions may represent the early stage of the changes seen in humans as tissue assessments 
in mutant mice are confined to immature skeleton before the inevitable death of these mice around 2–3 weeks of 
age.
All symptoms in Nlrp3LysM mice, including systemic inflammation, death and growth plate dysplasia are 
apparently abrogated upon Il-1 receptor ablation, but not stabilization of PARP1, a downstream target of inflam-
masome cascades and a negative regulator of bone resorption24. The role PARP1 in NLRP3LysM-mediated bone 
resorption is worth investigating, but is beyond the scope of this manuscript. Our results suggest that IL-1β is 
responsible for NLRP3-induced events investigated in this study; others find that genetic or pharmacological 
inhibition of IL-1 and/or IL-18 signaling provides partial efficacy in mouse disease models of MWS and FCAS37. 
These differences, which relate to the severity of residual disease, may stem from variables such as the efficiency of 
Cre drivers and mouse backgrounds. In fact, and most importantly, IL-1 blocking drugs are efficacious in resolv-
ing CAPS-associated inflammatory symptoms, but not bony outgrowths in human patients. In contrast, as noted 
above, all symptoms in Nlrp3LysM mice, including cartilage defects are prevented by inhibiting IL-1 signaling. 
Thus, skeletal lesions respond differently to inhibition of IL-1 signaling. However, it is likely that the absence of 
lesions in NOMID mice is a result of blockade of IL-1 signaling during development before the onset of growth 
plate dysplasia. Hence, it is plausible that early diagnosis and therapeutic intervention with IL-1 drugs in humans 
may prevent the development of skeletal manifestations.
The epiphysis of NOMID mice display pronounced hypoxia compared to WT littermates. Although the center 
of the epiphysis in developing bones is normally hypoxic33, our results show that hypoxia is exacerbated in mutant 
limbs by the excessive amounts of IL-1β, which cause severe anemia of inflammation. Accordingly, chronic expo-
sures to IL-1β are known to cause anemia through multiple mechanisms38, including attenuation of proliferation 
and differentiation of erythroid progenitors39, inhibition of erythropoietin production and signaling40, promotion 
of the biosynthesis of ferritin and down regulation of the expression of ferroportin41, 42, which enable the storage 
and the release of iron, respectively, by cells such as macrophages and hepatocytes. The specific mechanisms of 
anemia in NOMID mice are unclear, but this anomaly is associated with inflammation, and diminished expres-
sion of HIF-1α and its target genes, events that are associated with chondrocyte death. Although the sequence 
of events between chondrocyte loss and impaired hypoxic responses in the Nlrp3LysM model is unsettled, our 
results are consistent with the severe growth plate disorganization and hypocellularity occurring in mice lacking 
HIF-1α. Thus, irrespective of the hierarchy of the biological events, we posit that excessive amounts of IL-1β pro-
duced by hematopoietic cells create a cytotoxic environment in bone, thereby compromising the development of 
osteo-chondroprogenitors.
In conclusion, we report that IL-1β over-secretion caused by activated NLRP3 inflammasome in myeloid 
cells, but not mesenchymal cells, drives anemia, and hypoxia in the bone environment, ultimately promoting 
chondrocyte death, and the development of abnormal growth plate and epiphysis. Despite some dissimilarity 
in the phenotype of NOMID in humans and mice, growth plate disorganization and epiphyseal hypocellularity 
are common features of this disorder in both species. Thus, our results showing that disease manifestations in 
NOMID mice are prevented by IL-1 receptor ablation have clinical implications as they suggest that therapeutic 
intervention with IL-1 drugs prior to the onset of skeletal lesions may prevent the development of these devastat-
ing complications in humans.
Methods
Mice. IL-1 receptor-deficient (Il-1r−/−) mice were purchased from The Jackson Laboratory. Nlrp3fl(D301N)/+ 
mice14, Parp1D214N/D214N mice24, Ikk2fl/fl mice30, lysozyme M (LysM)-Cre mice43, collagen II (Col2)-Cre mice44 and 
Dermo-1 (DM1)-Cre mice45 have been previously described. All mice were on the C57BL6 background, and 
mouse genotyping was performed by PCR. All procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) of Washington University School of Medicine in St. Louis. All experiments were per-
formed in accordance with the relevant guidelines and regulations described in the IACUC-approved protocol 
#20160245.
Bone mass and microstructure. Femoral bone structure was analyzed by micro-computed tomography 
(µCT) system (μCT 40; Scanco Medical AG, Zurich) as previously described. Briefly, femora from male mice 
were stabilized in 2% agarose gel, and µCT scans at 45 kVp (2-week old bones) and 55 kVp (4-week old and older 
bones) were taken along the length of the femurs as previously described14, 24, 25. The volume of interest analyzed 
was located just proximal to the growth plate of the femur, spanning a height of 350 µm each for the metaphyseal 
region.
Histology, immunohistochemistry and in situ hybridization. Spleens were harvested and weighted 
immediately. Long bones were fixed in 10% formalin, decalcified in 14% (w/v) EDTA pH 7.2 for 10–14 days at 
room temperature, embedded in paraffin, sectioned at 5 μm thickness and mounted on glass slides. The sections 
were stained with H&E, safranin O or alcian blue as described previously14. For immunofluorescence, sections 
were incubated with 1% hyaluronidase (Sigma) for 30 minutes at 37 °C, rinsed with PBS and blocked with 10% 
goat serum for 1 hour at room temperature. The sections were then incubated overnight at 4 °C with rat polyclonal 
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type II collagen antisera or a rabbit polyclonal anti-IIA antibody that recognizes the exon 2-encoded cysteine-rich 
domain within the NH2-propeptide of type II procollagen as previously described14, 46. After washes in PBS, the 
sections were incubated for 1 hour at room temperature with secondary antibodies conjugated to either Alexa 
488 or Alexa 594 fluorescent dyes (Invitrogen). Following rinses in distilled water, DAPI containing mounting 
solution was applied to each tissue section. A Nikon Eclipse E800 fluorescence microscope was used to view the 
images. HIF-1α immunohistochemistry was carried as previously described47. In situ hybridization analyses were 
performed as previously described48 using 35S-labeled riboprobes on paraffin sections of bone specimens.
Hypoxyprobe labeling. Two-week-old wild type mice were injected intraperitoneally with 60 mg/kg 
hypoxyprobe-1 (pimonidazole HCl, Hypoxyprobe, Inc.) in PBS. Bones and (kidneys as a positive control) were 
isolated 75 minutes later and fixed overnight at 4 °C before further processing as previously described34. Mice that 
did not receive hypoxyprobe were analyzed in parallel to serve as a negative control for hypoxyprobe antibody 
specificity. Detection of hypoxyprobe binding was performed using the Hypoxyprobe-1 Plus Kit (Hypoxyprobe, 
Inc.) with the fluorescein isothiocyanate (FITC)-conjugated antibody diluted 1:100 in blocking buffer and 
employing a peroxidase-conjugated anti-FITC secondary antibody at 1:100.
Peripheral blood and bone marrow analyses. Complete blood counts were performed by the 
Washington University School of Medicine DCM Diagnostic Laboratory as previously described25. Bone marrow 
cells were flushed out as previously described25, and photographed.
Cell cultures. Bone marrow macrophages (BMM) were obtained by culturing mouse bone marrow cells in 
culture media containing a 1:25 dilution of supernatant from the fibroblastic cell line, CMG 14–12, as a source 
of M-CSF49, a mitogenic factor for BMM, for approximately 5 days in a 10-cm dish as previously described25. 
Nonadherent cells were removed by vigorous washes with PBS, and adherent BMM were detached with 
trypsin-EDTA, and cultured in culture media containing a 1:50 dilution of CMG at 5–10 × 103/well in a 96-well 
plate (for IL-1β analysis in conditioned media by ELISA) or 8 × 105/well in a 6-well plate (for Western blot analy-
sis). Chondrocytes were isolated from the ribs of 2-day old pups as previously described50, and plated at 1 × 106/
well in a 6-well plate in DMEM media containing 10% FBS.
To determine cell response in normoxic and hypoxic conditions, BMM treated with 100 ng/ml LPS for 3 hours, 
then with 5 mM ATP for 30 minutes or chondrocytes exposed to 10 ng/ml IL-1β (R&D Systems) for 24 hours, were 
maintained at 37 °C in a humidified atmosphere of 5% CO2, 20% O2 (normoxia) or 5% CO2, 2% O2 (hypoxia).
mRNA expression analysis. Total RNA was harvested from tibia, epiphysis or cultured chondrocytes using 
RNeasy Plus Mini Kit (Qiagen). Complementary DNA was then synthesized with iScript reverse transcription kit 
(Bio-Rad) and quantified using primers listed in Supplemental Table 1. Gene expression was analyzed by SYBR 
Green gene expression assay (Applied Biosystems).
Flow cytometry. Mouse bone marrow cells were prepared as described above. Splenocytes were isolated as 
previously described51. For flow cytometry analysis of the leukocytes, red blood cells were depleted with red blood 
cell lysis buffer (Roche). Cells (0.5–1 × 106) were incubated with Fc block (anti-mouse CD16/32, BioLegend) 
to block nonspecific Fc binding, stained with isotype control or FITC-anti-mouse CD11b (eBioscience) and 
PE-anti-mouse Ly-6G/Ly-6C (Gr1) antibody (Biolegend) according to the supplier’s instructions. For flow cytom-
etry analysis of red blood cells, whole mouse bone marrow cells or splenocytes were stained with isotype control 
or APC anti-mouse Ter119 (BioLegend) and BV-421 anti-mouse CD71 antibody (BD), according to the supplier’s 
instructions. Flow cytometry was performed using BD LSRFortessa or BD FACSCanto II Flow Cytometer system, 
followed by analysis with FlowJo software (Tree Star, Inc.).
Western blot analysis. Cell extracts were prepared by lysing cells with RIPA buffer (50 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 0.5% NaDOAc, 0.1% SDS, and 1.0%NP-40) plus phosphatase inhibitors (2 mMNaVO4, 
10 mMNaF, and 1 mMPMSF) and Complete Protease Inhibitor Cocktail (Roche). Protein concentrations were 
determined by the Bio-Rad method, and equal amounts of proteins were subjected to SDS-PAGE gels (8–15%). 
Proteins were transferred onto nitrocellulose membranes and incubated with NLRP3 antibody (1:1000; 
Adipogen), PARP-1, cleaved PARP-1 antibody (1:1000; Cell Signaling Technologies), or β-actin antibody (Santa 
Cruz Biotechnology) overnight at 4 °C, followed by a 1 h incubation with secondary goat anti-mouse IRDye 800 
(Rockland) or goat anti-rabbit Alexa-Fluor 680 (Molecular Probes), respectively. The results were visualized using 
Li-Cor Odyssey Infrared Imaging System (LI-COR Biosciences).
Immunoassays. BMM were plated at 5 × 104 cells per well on a 96-well plate and maintained for 24 h in 
culture media containing a 1:10 dilution of CMG. Cells were treated with 100 ng/ml LPS or PBS without changing 
media for 3 hours, then with 5 mM ATP for 30 minutes, and conditioned media were collected. For IL-1β levels 
in bone marrow, flushed bone marrow were centrifuged and the supernatants were collected as described previ-
ously25. IL-1β levels were quantified using the eBioscience ELISA kit.
Statistical analysis. Statistical analysis was performed using Student’s t-test, one-way ANOVA or two-way 
ANOVA with Tukey’s multiple comparisons test in GraphPad Prism 6.
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